CD19-specific T-cell therapy (B cell malignancies), Christie NHS Foundation Trust

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCD19-specific T-cell therapy (B cell malignancies), Christie NHS Foundation Trust
Drug Alias NameaCD19z cells
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 inhibitors
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesChristie Hospital Nhs Foundation TrustThe University Of ManchesterCancer Research UK
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChristie Hospital Nhs Foundation TrustThe University Of ManchesterCancer Research UK
Active IndicationsN/A
Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A